cilostazol has been researched along with Infarction, Middle Cerebral Artery in 17 studies
Infarction, Middle Cerebral Artery: NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our results suggest that phosphodiesterase 3 inhibitor cilostazol may have anti-depressant effects on post-stroke depression through inhibition of neurodegeneration in the primary lesion and secondary extrafocal sites and promotion of neurogenesis." | 7.83 | Anti-depressant effects of phosphodiesterase 3 inhibitor cilostazol in chronic mild stress-treated mice after ischemic stroke. ( Choi, BT; Hong, KW; Kim, HN; Kim, YR; Shin, HK, 2016) |
| "In the non-rtPA cohort, pretreatment by cilostazol significantly decreased the endothelial expression of adhesion molecules (P-selectin and intercellular adhesion molecule-1) and prevented platelet aggregation and leukocyte plugging in the microvessels after cerebral ischemia/reperfusion in the acute phase." | 7.78 | Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia. ( Fujita, Y; Hase, Y; Ihara, M; Ito, H; Kitamura, A; Maki, T; Nakabayashi, H; Okamoto, Y; Takahashi, R; Washida, K, 2012) |
| "To investigate the protective effect of cilostazol administrated intranasally on chronic injury after focal cerebral ischemia in mice." | 7.77 | [Protective effect of intranasal cilostazol administration on chronic injury after cerebral ischemia in mice]. ( Jiang, LL; Li, Q; Wei, EQ; Ye, YL; Yu, YP; Zhang, Q; Zhang, WP, 2011) |
| "Our results suggest that phosphodiesterase 3 inhibitor cilostazol may have anti-depressant effects on post-stroke depression through inhibition of neurodegeneration in the primary lesion and secondary extrafocal sites and promotion of neurogenesis." | 3.83 | Anti-depressant effects of phosphodiesterase 3 inhibitor cilostazol in chronic mild stress-treated mice after ischemic stroke. ( Choi, BT; Hong, KW; Kim, HN; Kim, YR; Shin, HK, 2016) |
| " He was thought to have had an embolic stroke and was initially treated with warfarin." | 3.80 | Repeated episodes of ischemic stroke over a short period in a patient with essential thrombocythemia on anticoagulant therapy. ( Hirano, T; Isoda, K; Ito, K; Naganuma, M; Nishi, S, 2014) |
| "In the non-rtPA cohort, pretreatment by cilostazol significantly decreased the endothelial expression of adhesion molecules (P-selectin and intercellular adhesion molecule-1) and prevented platelet aggregation and leukocyte plugging in the microvessels after cerebral ischemia/reperfusion in the acute phase." | 3.78 | Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia. ( Fujita, Y; Hase, Y; Ihara, M; Ito, H; Kitamura, A; Maki, T; Nakabayashi, H; Okamoto, Y; Takahashi, R; Washida, K, 2012) |
| "To investigate the protective effect of cilostazol administrated intranasally on chronic injury after focal cerebral ischemia in mice." | 3.77 | [Protective effect of intranasal cilostazol administration on chronic injury after cerebral ischemia in mice]. ( Jiang, LL; Li, Q; Wei, EQ; Ye, YL; Yu, YP; Zhang, Q; Zhang, WP, 2011) |
| "Cilostazol treatment significantly reduced the percentage of 8-OHdG-positive neurons (65." | 1.42 | Neuroprotective effects of cilostazol are mediated by multiple mechanisms in a mouse model of permanent focal ischemia. ( Abumiya, T; Hokari, M; Houkin, K; Kazumata, K; Kuroda, S; Nakayama, N; Shichinohe, H; Tan, C, 2015) |
| "We report a 60-year-old woman with idiopathic thrombocytopenic purpura who experienced acute infarction of the middle cerebral artery." | 1.40 | Elevated platelet microparticle levels after acute ischemic stroke with concurrent idiopathic thrombocytopenic purpura. ( Ichijo, M; Ishibashi, S; Mizusawa, H; Nomura, S; Ohkubo, T; Sanjo, N; Yokota, T, 2014) |
| "Mice subjected to 6-h middle cerebral artery occlusion were treated with delayed tPA alone at 6 h, with combined tPA plus cilostazol at 6 h, or with vehicle at 6 h." | 1.36 | Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA. ( Chen, H; Fujiwara, Y; Hara, H; Ishiguro, M; Iwama, T; Izuta, H; Mishiro, K; Satoh, M; Shimazawa, M; Tsuruma, K; Yoshimura, S, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nan, D | 1 |
| Jin, H | 1 |
| Deng, J | 1 |
| Yu, W | 1 |
| Liu, R | 1 |
| Sun, W | 1 |
| Huang, Y | 1 |
| Ichijo, M | 1 |
| Ishibashi, S | 1 |
| Ohkubo, T | 1 |
| Nomura, S | 1 |
| Sanjo, N | 1 |
| Yokota, T | 1 |
| Mizusawa, H | 1 |
| Toda, Y | 1 |
| Katsura, K | 1 |
| Saito, M | 1 |
| Inaba, T | 1 |
| Sakurazawa, M | 1 |
| Katayama, Y | 1 |
| Shichinohe, H | 1 |
| Tan, C | 1 |
| Abumiya, T | 1 |
| Nakayama, N | 1 |
| Kazumata, K | 1 |
| Hokari, M | 1 |
| Houkin, K | 1 |
| Kuroda, S | 1 |
| Kim, YR | 1 |
| Kim, HN | 1 |
| Hong, KW | 4 |
| Shin, HK | 2 |
| Choi, BT | 1 |
| Nagai, N | 1 |
| Yoshioka, C | 1 |
| Ito, Y | 1 |
| Funakami, Y | 1 |
| Nishikawa, H | 1 |
| Kawabata, A | 1 |
| Yuzawa, I | 1 |
| Yamada, M | 1 |
| Fujii, K | 1 |
| Nonaka, Y | 1 |
| Tsuruma, K | 2 |
| Shimazawa, M | 2 |
| Yoshimura, S | 2 |
| Iwama, T | 2 |
| Hara, H | 2 |
| Ishiguro, M | 1 |
| Mishiro, K | 1 |
| Fujiwara, Y | 1 |
| Chen, H | 1 |
| Izuta, H | 1 |
| Satoh, M | 1 |
| Zhang, Q | 1 |
| Ye, YL | 1 |
| Li, Q | 1 |
| Zhang, WP | 1 |
| Jiang, LL | 1 |
| Wei, EQ | 1 |
| Yu, YP | 1 |
| Hase, Y | 1 |
| Okamoto, Y | 1 |
| Fujita, Y | 1 |
| Kitamura, A | 1 |
| Nakabayashi, H | 1 |
| Ito, H | 1 |
| Maki, T | 1 |
| Washida, K | 1 |
| Takahashi, R | 1 |
| Ihara, M | 1 |
| Naganuma, M | 1 |
| Isoda, K | 1 |
| Nishi, S | 1 |
| Ito, K | 1 |
| Hirano, T | 1 |
| Lee, JH | 4 |
| Kim, KY | 1 |
| Lee, YK | 1 |
| Park, SY | 3 |
| Kim, CD | 3 |
| Lee, WS | 3 |
| Rhim, BY | 2 |
| Kwon, SU | 1 |
| Cho, YJ | 1 |
| Koo, JS | 1 |
| Bae, HJ | 1 |
| Lee, YS | 1 |
| Hong, KS | 1 |
| Kim, JS | 1 |
| Nishimura, K | 1 |
| Ishigooka, J | 1 |
| Imamura, Y | 1 |
| Ihara, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for cilostazol and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis.
Topics: Aged; Angiography; Arteries; Aspirin; Brain; Cilostazol; Constriction, Pathologic; Disease Progressi | 2005 |
16 other studies available for cilostazol and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Cilostazol ameliorates ischemia/reperfusion-induced tight junction disruption in brain endothelial cells by inhibiting endoplasmic reticulum stress.
Topics: Animals; Blood-Brain Barrier; Cells, Cultured; Cilostazol; Cyclic AMP; Drug Evaluation, Preclinical; | 2019 |
Elevated platelet microparticle levels after acute ischemic stroke with concurrent idiopathic thrombocytopenic purpura.
Topics: Blood Platelets; Cell-Derived Microparticles; Cerebral Angiography; Cilostazol; Cyclosporine; Dexame | 2014 |
The effect of cilostazol and aspirin pre-treatment against subsequent transient focal cerebral ischemia in rat.
Topics: Aldehydes; Animals; Aspirin; bcl-2-Associated X Protein; Brain; Cilostazol; Cyclooxygenase 2; Drug T | 2014 |
Neuroprotective effects of cilostazol are mediated by multiple mechanisms in a mouse model of permanent focal ischemia.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Brain; Brain Ischemia; Cilostazol; CREB-Binding Protein; Deoxy | 2015 |
Anti-depressant effects of phosphodiesterase 3 inhibitor cilostazol in chronic mild stress-treated mice after ischemic stroke.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cilostazol; Corpus Striatum; Cyclic AMP Response Element | 2016 |
Intravenous Administration of Cilostazol Nanoparticles Ameliorates Acute Ischemic Stroke in a Cerebral Ischemia/Reperfusion-Induced Injury Model.
Topics: Administration, Intravenous; Animals; Blood Pressure; Brain; Cilostazol; Infarction, Middle Cerebral | 2015 |
An oral administration of cilostazol before focal ischemia reduces the infarct volume with delayed cerebral blood flow increase in rats.
Topics: Administration, Oral; Animals; Brain Ischemia; Cerebrovascular Circulation; Cilostazol; Infarction, | 2008 |
Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage.
Topics: Animals; Brain; Brain Ischemia; Cerebral Hemorrhage; Cerebral Infarction; Cilostazol; Disease Models | 2009 |
Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA.
Topics: Animals; Astrocytes; Blood-Brain Barrier; Brain Ischemia; Cilostazol; Cyclic Nucleotide Phosphodiest | 2010 |
[Protective effect of intranasal cilostazol administration on chronic injury after cerebral ischemia in mice].
Topics: Administration, Intranasal; Animals; Brain; Brain Ischemia; Cilostazol; Disease Models, Animal; Infa | 2011 |
Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia.
Topics: Administration, Oral; Animals; Antigens, CD; Brain; Brain Edema; Brain Ischemia; Calcium-Binding Pro | 2012 |
Repeated episodes of ischemic stroke over a short period in a patient with essential thrombocythemia on anticoagulant therapy.
Topics: Aged; Anticoagulants; Aphasia; Brain Ischemia; Cerebral Angiography; Cilostazol; Diffusion Magnetic | 2014 |
Cilostazol prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation in rats.
Topics: Animals; Blood-Brain Barrier; Blotting, Western; Brain Ischemia; Casein Kinase II; Chromosomes; Cilo | 2004 |
Poly(ADP-ribose) polymerase inhibition by cilostazol is implicated in the neuroprotective effect against focal cerebral ischemic infarct in rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis Inducing Factor; CD11 Antigens; Cilostaz | 2007 |
Beneficial synergistic effects of concurrent treatment with cilostazol and probucol against focal cerebral ischemic injury in rats.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Brain Ischemia; Caspase 3; Cerebral Infarction; Chemot | 2007 |
Cilostazol, a cAMP phosphodiesterase 3 inhibitor, in the treatment of poststroke depression.
Topics: Cilostazol; Depressive Disorder; Humans; Infarction, Middle Cerebral Artery; Male; Middle Aged; Phos | 2007 |